期刊文献+

临床药师对严重胰岛素抵抗2型糖尿病患者的用药分析 被引量:3

Analysis of Clinical Pharmacists Participating in the Drug Use of Type 2 Diabetes Mellitus Patients with Severe Insulin Resistance
下载PDF
导出
摘要 目的:探讨严重胰岛素抵抗2型糖尿病患者的综合治疗方案。方法:通过查阅文献,参考国内外指南,临床药师总结了改善胰岛素抵抗降糖药物的特点,并制定2型糖尿病患者胰岛素抵抗处理路线图。结果:结合患者病情,参照胰岛素抵抗处理路线图,为患者制定个体化治疗方案,患者血糖明显改善,胰岛素抵抗减轻,且无明显低血糖反应。结论:临床药师参与严重胰岛素抵抗2型糖尿病患者的治疗,保证了治疗的有效性和安全性,起到了积极的作用。 Objective: To explore the comprehensive treatment method for the type 2 diabetic patients with severe insulin resistance. Methods: According to the literature review and the relevant guidelines,clinical pharmacists summarized the characteristics of hypoglycemic drugs that can improve insulin resistance and formulated the flow chart for insulin resistance in patients with type 2 diabetes mellitus. Results: Based on the characteristics of the patients and the flow chart for insulin resistance, clinical pharmacists proposed individualized treatment plans that achieved significant improvement in glycemic control and reduction in insulin resistance without significant hypoglycemia. Conclusion: By participating in treating severe insulin resistance in patients with type 2 diabetes mellitus, clinical pharmacists played a positive role for ensuring the effectiveness and safety of therapy.
出处 《药学与临床研究》 2015年第2期178-181,共4页 Pharmaceutical and Clinical Research
关键词 临床药师 2型糖尿病 胰岛素抵抗 Clinical pharmacist Type 2 diabetes mellitus Insulin resistance
  • 相关文献

参考文献4

二级参考文献52

  • 1Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes:a patient centered approach Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2012.35,1364-1379.
  • 2lnzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2012,55:1577 1596.
  • 3Stratton IM, Adler AI, Nell HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000, 321:405-412.
  • 4UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998 352:837 853.
  • 5Holman RR, Paul SK, Bethel MA, Matthews DR, Neff HA 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008, 359:1577 1589.
  • 6Gerstein HC, Miller ME, Byington RP, et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med, 2008, 358:2545-2559.
  • 7Vasilakou D, Karagiannls T, Athanasiadou E, et al. Sodium glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review andmetaanalysis. Ann Intern Med, 2013 159:262-274.
  • 8StenlSf K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab, 2013, 15:372 382.
  • 9Schernthaner G, Gross JL, Rosenstock J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52 week randomized trial. Diabetes Care 2013, 36:2508-2515.
  • 10Roden M, Weng J, Eilbracbt J, et al. EMPAREG MONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double blind, placebo-controlled, phase 3 trial Lancet Diabetes Endocrinol, 2013, 1:208-219.

共引文献6782

同被引文献26

引证文献3

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部